These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30627273)

  • 1. Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study.
    Sato A; Takei M; Hiramatsu K; Takeda T; Miyamoto T; Yamazaki M; Sato Y; Komatsu M
    J Clin Med Res; 2019 Jan; 11(1):15-20. PubMed ID: 30627273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
    Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
    J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes.
    Ishii H; Ohkubo Y; Takei M; Nishio S; Yamazaki M; Kumagai M; Sato Y; Suzuki S; Aoki Y; Miyamoto T; Kakizawa T; Sakuma T; Komatsu M
    J Clin Med Res; 2014 Apr; 6(2):127-32. PubMed ID: 24578754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study.
    Devarajan TV; Venkataraman S; Kandasamy N; Oomman A; Boorugu HK; Karuppiah SKP; Balat D
    Indian J Endocrinol Metab; 2017; 21(5):745-750. PubMed ID: 28989886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
    Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N;
    Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).
    Kesavadev J; Pillai PBS; Shankar A; Krishnan G; Jothydev S
    Endocr Connect; 2017 Nov; 6(8):748-757. PubMed ID: 28982699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).
    Yokoyama H; Hirao K; Yamaguchi K; Oishi M; Lee G; Yagi N; Takamura H; Kashiwagi A
    Jpn Clin Med; 2014; 5():33-41. PubMed ID: 25288908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
    Chung HS; Lee MK
    Diabetes Metab J; 2011 Aug; 35(4):411-7. PubMed ID: 21977462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.
    Kim HM; Lim JS; Lee BW; Kang ES; Lee HC; Cha BS
    Endocrinol Metab (Seoul); 2015 Mar; 30(1):84-91. PubMed ID: 25325279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
    Muthukrishnan J; Dawra S; Marwaha V; Bishnoi JS; Narayanan CS
    Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S474-6. PubMed ID: 23565471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
    Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K
    Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
    Gudipaty L; Rosenfeld NK; Fuller CS; Gallop R; Schutta MH; Rickels MR
    Diabetes Care; 2014 Sep; 37(9):2451-8. PubMed ID: 24969577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
    Kato H; Nagai Y; Ohta A; Tenjin A; Nakamura Y; Tsukiyama H; Sasaki Y; Fukuda H; Ohshige T; Terashima Y; Sada Y; Kondo A; Sasaoka T; Tanaka Y
    Diabetes Res Clin Pract; 2015 Jul; 109(1):199-205. PubMed ID: 25934525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
    Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study.
    Xiao X; Cui X; Zhang J; Han Z; Xiao Y; Chen N; Li B; Cheng M; Gao H; Tang K
    Exp Ther Med; 2016 Nov; 12(5):3002-3008. PubMed ID: 27882107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.